Skip to main content

Table 2 Planned and actual dosing regimens and injections (FAS)

From: Intravitreal aflibercept for the treatment of patients with neovascular age-related macular degeneration in routine clinical practice in Latin America: the AQUILA study

 

Treatment-naïve (n = 201)

Previously treated (n = 73)

Overall (n = 274)

Planned dosing regimen

 T&E from initial treatment

51 (25.4)

8 (11.0)

59 (21.5)

 3 initial monthly injections, then T&E

84 (41.8)

31 (42.5)

115 (42.0)

 3 initial monthly injections, then every other month

5 (2.5)

4 (5.5)

9 (3.3)

 Treat until dry, then T&E

12 (6.0)

19 (26.0)

31 (11.3)

 Treat until dry, then PRN

20 (10.0)

2 (2.7)

22 (8.0)

 PRN from initial treatment

17 (8.5)

6 (8.2)

23 (8.4)

 Other

12 (6.0)

3 (4.1)

15 (5.5)

Reported dosing regimena

 T&E from initial treatment

43 (21.4)

7 (9.6)

50 (18.3)

 3 initial monthly injections, then T&E

40 (19.9)

25 (34.3)

65 (23.7)

 3 initial monthly injections, then every other month

9 (4.5)

2 (2.7)

11 (4.0)

 Treat until dry, then T&E

12 (6.0)

18 (24.7)

30 (11.0)

 Treat until dry, then PRN

51 (25.4)

5 (6.9)

56 (20.4)

 PRN from initial treatment

21 (10.5)

8 (11.0)

29 (10.6)

 3 initial monthly injections not completed

7 (3.5)

4 (5.5)

11 (4.0)

 Other

18 (9.0)

4 (5.5)

22 (8.0)

IVT-AFL injections by month 6 (mean ± SD)

3.1 ± 0.9

3.6 ± 1.3

3.2 ± 1.1

IVT-AFL injections by month 12 (mean ± SD)

4.2 ± 1.9

5.2 ± 2.7

4.4 ± 2.2

 ≥ 3 injections within 3 months

127 (63.2)

43 (58.9)

170 (62.0)

 ≥ 7 injections within 12 months

24 (11.9)

23 (31.5)

47 (17.2)

  1. Data are n (%) unless otherwise stated
  2. FAS full analysis set, IVT-AFL intravitreal aflibercept, PRN pro re nata, SD standard deviation, T&E treat and extend
  3. aAs reported by the investigator(s)